Fewer than 10% of individuals that would benefit from obesity jabs like Wegovy are able to get them, caution the World Health Organization as it releases its first recommendations on the medications.
Considering over a billion individuals worldwide now classified as obese, it is urging broader and more equitable availability to GLP-1 medication.
Per forecasts, in excess of 2,000,000,000 are projected to be obese by 2030 if no action is taken.
"The new guidelines affirms that obesity is a lifelong illness that can be managed with holistic and ongoing treatment," stated its chief Tedros Adhanom Ghebreyesus.
Substantial prices, insufficient output, and distribution challenges are significant hurdles to widespread access to the injections that can aid individuals in losing significant body mass, explains the organization.
Skinny Jab Shortage
Despite the present most optimistic case, the production of such drugs might only reach approximately 100 million people – less than 10% of eligible patients, per the WHO.
The guideline calls on nations and manufacturers to expand access, through measures like patent sharing.
Exclusive production rights on a key compound – the main ingredient of a leading brand – is due to expire in several nations in 2026.
The Way Obesity Injections Function
The injections mimick a natural hormone to delay gastric emptying, curb appetite and boost satiety so users eat less.
Patients usually begin shedding pounds after several weeks of commencing the weekly injections.
Studies indicates people may regain a significant portion a year later of stopping the treatment, because their normal appetite come back.
Being carrying excess weight increases your chance for experiencing diseases, like diabetes, cardiovascular issues, stroke, and some cancers.
Excess weight affects individuals in every country and was responsible for 3.7 million deaths worldwide in 2024, per the WHO.
